These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38782386)

  • 1. Comparison of the two histological subtypes of ampullary adenocarcinoma: a retrospective study.
    Xu ZY; Guan J; Zhang ZY; Liu DW; Li XD; Zhou ZQ
    Cir Cir; 2024; 92(2):159-164. PubMed ID: 38782386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
    Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
    J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
    Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
    J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumors of the ampulla of vater: histopathologic classification and predictors of survival.
    Carter JT; Grenert JP; Rubenstein L; Stewart L; Way LW
    J Am Coll Surg; 2008 Aug; 207(2):210-8. PubMed ID: 18656049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
    Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
    HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic Subtypes of Ampullary Adenocarcinoma: Value of Ampullary MDCT for Noninvasive Preoperative Differentiation.
    Ivanovic AM; Alessandrino F; Maksimovic R; Micev M; Ostojic S; Gore RM; Mortele KJ
    AJR Am J Roentgenol; 2017 Mar; 208(3):W71-W78. PubMed ID: 28095024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
    Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
    Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer.
    Park HM; Park SJ; Han SS; Hong SK; Hong EK; Kim SW
    Medicine (Baltimore); 2019 Nov; 98(44):e17711. PubMed ID: 31689805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?
    Westgaard A; Pomianowska E; Clausen OP; Gladhaug IP
    Ann Surg Oncol; 2013 Feb; 20(2):430-9. PubMed ID: 22956064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma.
    Westgaard A; Tafjord S; Farstad IN; Cvancarova M; Eide TJ; Mathisen O; Clausen OP; Gladhaug IP
    BMC Cancer; 2008 Jun; 8():170. PubMed ID: 18547417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in adenocarcinoma of the ampulla of Vater].
    Fernández Aceñero MJ; Martínez Useros J; Díez-Valladares L; Ortega-Medina L; Pérez Aguirre E; de la Serna Esteban S; García Botella S; Díaz Del Arco C
    Rev Esp Patol; 2018; 51(4):210-215. PubMed ID: 30269771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.
    Ang DC; Shia J; Tang LH; Katabi N; Klimstra DS
    Am J Surg Pathol; 2014 Oct; 38(10):1371-9. PubMed ID: 24832159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Intra-Ampullary Papillary-Tubular Neoplasm versus Flat Dysplasia as Precursor Lesions of Ampullary Adenocarcinoma.
    Han S; Jang KT; Choi DW; Choi SH; Heo JS; Han IW; Park D; Ryu Y
    Dig Surg; 2020; 37(6):505-514. PubMed ID: 33080609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma.
    Zimmermann C; Wolk S; Aust DE; Meier F; Saeger HD; Ehehalt F; Weitz J; Welsch T; Distler M
    Sci Rep; 2019 Sep; 9(1):12676. PubMed ID: 31481741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
    Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
    Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
    Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampullary adenocarcinoma - differentiation matters.
    Schirmacher P; Büchler MW
    BMC Cancer; 2008 Sep; 8():251. PubMed ID: 18761739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry.
    Kumari N; Prabha K; Singh RK; Baitha DK; Krishnani N
    Hum Pathol; 2013 Oct; 44(10):2213-9. PubMed ID: 23834763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.